TY - JOUR
T1 - Novel Diselenide Bis-Schiff bases tagged with diphenyl ethers
T2 - Promising candidates for selective treatment of hypopharyngeal and breast adenocarcinoma
AU - Hammouda, Mohamed M.
AU - Shaaban, Saad
AU - Ba-Ghazal, Hussein
AU - Dawood, Amal F.
AU - Zeidan, Mohamed A.
AU - Al Khatib, Arwa Omar
AU - Alatawi, Fatema S.
AU - Alomari, Khadra B.
AU - Sharaky, Marwa
AU - Alaasar, Mohamed
AU - Al-Karmalawy, Ahmed A.
N1 - Publisher Copyright:
© 2025 Elsevier Inc.
PY - 2025/8
Y1 - 2025/8
N2 - Organoselenium (OSe) compounds have received much attention due to their potential to inhibit tumor growth while also protecting cells from oxidative damage, making them promising cancer prevention agents. However, diphenyl diselenide (Ph2Se2) has many drawbacks, such as increased lipophilicity with low oral bioavailability, toxicity issues due to poor selectivity, and limited physicochemical criteria. In this study, we developed two novel sets of diphenyl ether 5a-g and diphenyl ether hybridized with diselenide 6a-g and evaluated their anticancer activity and underlying cytotoxic mechanisms. Utilizing the growth inhibition percentage (GI%) assay, the anticancer activity of the newly synthesized candidates was evaluated against fifteen cancer cell lines. Furthermore, their potential safety and selectivity were tested against human skin fibroblast (HSF) cells. The analysis of structure-activity relationships (SAR) revealed that the human hypopharyngeal cancer cell line (FaDu) and human breast cancer cell line (MDA-MB-468) were the most sensitive to their growth inhibition effect. IC50 values were measured against the most sensitive ones (FaDu, MDA-MB-468, HCT-116, HELA, and A549 cells), where compounds 5b, 5c, and 6a manifested the highest mean IC50 values of 5.71, 4.49, and 6.22 μg/mL, respectively. Furthermore, the superior anticancer candidates 5b, 5c, and 6a were tested for apoptotic activity against a panel of apoptotic and anti-apoptotic markers. Moreover, compounds 5b, 5c, and 6a were estimated against inflammatory markers such as COX ІІ, IL-6, and IL-1β. Besides, the lead compounds (5b, 5c, and 6a) were docked against Caspase-6 and BCL-2 target receptors to investigate their apoptotic potential. Overall, candidates 5b, 5c, and 6a showed an attractive cytotoxic potential as anticancer agents with high selectivity towards hypopharyngeal and breast cancers with apoptotic and anti-inflammatory effects. Indeed, they provided a promising rationale for optimization studies and further mechanistic investigations to estimate their therapeutic potential.
AB - Organoselenium (OSe) compounds have received much attention due to their potential to inhibit tumor growth while also protecting cells from oxidative damage, making them promising cancer prevention agents. However, diphenyl diselenide (Ph2Se2) has many drawbacks, such as increased lipophilicity with low oral bioavailability, toxicity issues due to poor selectivity, and limited physicochemical criteria. In this study, we developed two novel sets of diphenyl ether 5a-g and diphenyl ether hybridized with diselenide 6a-g and evaluated their anticancer activity and underlying cytotoxic mechanisms. Utilizing the growth inhibition percentage (GI%) assay, the anticancer activity of the newly synthesized candidates was evaluated against fifteen cancer cell lines. Furthermore, their potential safety and selectivity were tested against human skin fibroblast (HSF) cells. The analysis of structure-activity relationships (SAR) revealed that the human hypopharyngeal cancer cell line (FaDu) and human breast cancer cell line (MDA-MB-468) were the most sensitive to their growth inhibition effect. IC50 values were measured against the most sensitive ones (FaDu, MDA-MB-468, HCT-116, HELA, and A549 cells), where compounds 5b, 5c, and 6a manifested the highest mean IC50 values of 5.71, 4.49, and 6.22 μg/mL, respectively. Furthermore, the superior anticancer candidates 5b, 5c, and 6a were tested for apoptotic activity against a panel of apoptotic and anti-apoptotic markers. Moreover, compounds 5b, 5c, and 6a were estimated against inflammatory markers such as COX ІІ, IL-6, and IL-1β. Besides, the lead compounds (5b, 5c, and 6a) were docked against Caspase-6 and BCL-2 target receptors to investigate their apoptotic potential. Overall, candidates 5b, 5c, and 6a showed an attractive cytotoxic potential as anticancer agents with high selectivity towards hypopharyngeal and breast cancers with apoptotic and anti-inflammatory effects. Indeed, they provided a promising rationale for optimization studies and further mechanistic investigations to estimate their therapeutic potential.
KW - Apoptosis
KW - Breast cancer
KW - Diphenyl ether
KW - Diselenides
KW - Hypopharyngeal carcinoma
UR - http://www.scopus.com/inward/record.url?scp=105008528604&partnerID=8YFLogxK
U2 - 10.1016/j.bioorg.2025.108670
DO - 10.1016/j.bioorg.2025.108670
M3 - Article
AN - SCOPUS:105008528604
SN - 0045-2068
VL - 163
JO - Bioorganic Chemistry
JF - Bioorganic Chemistry
M1 - 108670
ER -